| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.063 | 0.3 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.3 |